Team:Austin Texas/Safety

From 2012.igem.org

(Difference between revisions)
Line 19: Line 19:
-
1. Would any of your project ideas raise safety issues in terms of:<br>
+
'''1. Would any of your project ideas raise safety issues in terms of:<br>'''
-
a. researcher safety,<br>
+
'''a. researcher safety,<br>'''
Our host organism, ''E. coli'' B, is non-pathogenic. Our project does make use of N-3-oxo-dodecanoyl-L-Homoserine lactone to induce the production of our recombinase. Exposure of this auto-inducer through skin or eyes or inhalation or ingestion can result in dizziness, drowsiness, headache nausea and vomiting.<br>
Our host organism, ''E. coli'' B, is non-pathogenic. Our project does make use of N-3-oxo-dodecanoyl-L-Homoserine lactone to induce the production of our recombinase. Exposure of this auto-inducer through skin or eyes or inhalation or ingestion can result in dizziness, drowsiness, headache nausea and vomiting.<br>
-
b. public safety, or<br>
+
'''b. public safety, or<br>'''
In our model, N-3-oxo-dodecanoyl-L-Homoserine lactone works with LasR to induce CRE recombinase. ''Pseudomonas aeruginosa'' uses a similar pathway, in which the autoinducer binds to LasR, promoting the expression of various virulence factors tied to infection.<br>
In our model, N-3-oxo-dodecanoyl-L-Homoserine lactone works with LasR to induce CRE recombinase. ''Pseudomonas aeruginosa'' uses a similar pathway, in which the autoinducer binds to LasR, promoting the expression of various virulence factors tied to infection.<br>
-
c. environmental safety?<br>
+
'''c. environmental safety?<br>'''
Depletion of global caffeine supplies?
Depletion of global caffeine supplies?
-
2. Do any of the new BioBrick parts (or devices) that you made this year raise any safety issues? If yes,<br>
+
'''2. Do any of the new BioBrick parts (or devices) that you made this year raise any safety issues? If yes,<br>'''
-
a. did you document these issues in the Registry?<br>
+
'''a. did you document these issues in the Registry?<br>'''
-
b. how did you manage to handle the safety issue?<br>
+
'''b. how did you manage to handle the safety issue?<br>'''
-
c. How could other teams learn from your experience?<br>
+
'''c. How could other teams learn from your experience?<br>'''
-
3. Is there a local biosafety group, committee, or review board at your institution?<br>
+
'''3. Is there a local biosafety group, committee, or review board at your institution?<br>'''
-
a. If yes, what does your local biosafety group think about your project?<br>
+
Yes, UT's Institutional Biosafety Committee (http://www.utexas.edu/research/rsc/ibc/) reviews research involving potentially dangerous biological agents and substances.
-
b. If no, which specific biosafety rules or guidelines do you have to consider in your country?<br>
+
'''a. If yes, what does your local biosafety group think about your project?<br>'''
 +
Well...
 +
'''b. If no, which specific biosafety rules or guidelines do you have to consider in your country?<br>'''
-
4. Do you have any other ideas how to deal with safety issues that could be useful for future iGEM competitions? How could parts, devices and systems be made even safer through biosafety engineering?
+
'''4. Do you have any other ideas how to deal with safety issues that could be useful for future iGEM competitions? How could parts, devices and systems be made even safer through biosafety engineering?'''

Revision as of 20:55, 21 August 2012


Use this page to answer the questions on the safety page.


1. Would any of your project ideas raise safety issues in terms of:
a. researcher safety,
Our host organism, E. coli B, is non-pathogenic. Our project does make use of N-3-oxo-dodecanoyl-L-Homoserine lactone to induce the production of our recombinase. Exposure of this auto-inducer through skin or eyes or inhalation or ingestion can result in dizziness, drowsiness, headache nausea and vomiting.
b. public safety, or
In our model, N-3-oxo-dodecanoyl-L-Homoserine lactone works with LasR to induce CRE recombinase. Pseudomonas aeruginosa uses a similar pathway, in which the autoinducer binds to LasR, promoting the expression of various virulence factors tied to infection.
c. environmental safety?
Depletion of global caffeine supplies?

2. Do any of the new BioBrick parts (or devices) that you made this year raise any safety issues? If yes,
a. did you document these issues in the Registry?
b. how did you manage to handle the safety issue?
c. How could other teams learn from your experience?

3. Is there a local biosafety group, committee, or review board at your institution?
Yes, UT's Institutional Biosafety Committee (http://www.utexas.edu/research/rsc/ibc/) reviews research involving potentially dangerous biological agents and substances. a. If yes, what does your local biosafety group think about your project?
Well... b. If no, which specific biosafety rules or guidelines do you have to consider in your country?

4. Do you have any other ideas how to deal with safety issues that could be useful for future iGEM competitions? How could parts, devices and systems be made even safer through biosafety engineering?